|
|
|
|
|
by Moter8
2737 days ago
|
|
Citing a part of the first paper's Conclusion: > Until data from well-designed clinical trials are available and reliable, and standardized CBD products that are produced using GMP are available, caution must be exercised in any consideration of using CBD for the treatment of epilepsy. In the meantime, based upon promising preliminary data, further clinical research should be wholeheartedly pursued. Citing a part of the second paper's Conclusion: > Human experimental findings support preclinical findings, and also suggest a lack of anxiogenic effects, minimal sedative effects, and an excellent safety profile. Current preclinical and human findings mostly involve acute CBD dosing in healthy subjects, so further studies are required to establish whether chronic dosing of CBD has similar effects in relevant clinical populations. Overall, this review emphasizes the potential value and need for further study of CBD in the treatment of anxiety disorders. So the second one says it seems good for acute dosing. Both say more research has to be done. Let's hope this is being done in the near future. |
|
Things have changed some in recent years, but it’s still very difficult to do accredited scientific research when something is a scheduled narcotic.